Theravance Biopharma (TBPH) Liabilities and Shareholders Equity (2013 - 2026)

Theravance Biopharma (TBPH) has 14 years of Liabilities and Shareholders Equity data on file, last reported at $472.3 million in Q1 2026.

• On a quarterly basis, Liabilities and Shareholders Equity rose 37.47% year-over-year to $472.3 million in Q1 2026; TTM through Mar 2026 was $1.8 billion, a 27.09% increase from a year earlier, with the FY2025 full-year figure at $485.6 million, up 37.1% from the prior year.
• Liabilities and Shareholders Equity for Q1 2026 stood at $472.3 million, down from $485.6 million in the prior quarter.
• Over the last five years, Liabilities and Shareholders Equity for TBPH reached as high as $763.5 million in Q3 2022 and fell as low as $343.6 million in Q1 2025.
• Historically, Liabilities and Shareholders Equity has averaged $438.5 million across 5 years, with a median of $413.6 million in 2023.
• Across the five-year window, Liabilities and Shareholders Equity surged 89.4% in 2022 and tumbled 45.83% in 2023, its largest moves.
• Year by year, Liabilities and Shareholders Equity stood at $607.4 million in 2022, then sank by 37.11% to $382.0 million in 2023, then retreated by 7.29% to $354.2 million in 2024, then soared by 37.1% to $485.6 million in 2025, then declined by 2.73% to $472.3 million in 2026.
• Per Business Quant data, the three most recent Liabilities and Shareholders Equity figures were $472.3 million in Q1 2026, $485.6 million in Q4 2025, and $415.5 million in Q3 2025.